Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients

British Journal of Clinical Pharmacology

Volumn 59, Issue 4, 2005, Pages 398-404

  Van Heeswijk, Rolf P G ^a,b   Bourbeau, M ^b   Seguin, I ^a   Giguere, P ^a   Garber, G E ^a,b   Cameron, D W ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Circadian; HIV; Lopinavir; Pharmacokinetics; Ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR;

ABDOMINAL CRAMP; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS SPECTROMETRY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR;

EID: 17144373316     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02337.x     Document Type: Article

References (30)

1. Bruguerolle B. Chronopharmacokinetics. Current status. Clin Pharmacokinet 1998; 35: 83-94.
2. Bortolotti Annese V, Coccia G. Twenty-four hour ambulatory antroduodenal manometry in normal subjects (co-operative study). Neurogastroenterol Mot 2000; 12: 231-8.
3. Lemmer B, Nold G. Circadian effects in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol 1991; 32: 627-9.3.
4. Ohno M, Yamaguchi I, Ito T, Saiki K, Yammamoto I, Zuma J. Circadian variation of the urinary 6β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A4 activity. Eur J Clin Pharmacokinet 2000; 55: 861-5.
5. Hsu A, Granneman R, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41: 898-905.
6. Justesen US, Pedersen C. Diurnal variation of plasma protease inhibitor concentrations. AIDS 2002; 16: 2487-9.
7. Erol K, Kilic FS, Batu OS, Yildirim E. Morning-evening administration time differences in digoxin kinetics in healthy young subjects. Chronobiol Int 2001; 18: 841-9.
8. Lemmer B, Nold G, Behne S, Kaiser R. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int 1991; 8: 485-94.
9. Choi J, Chong-Kook K, Lee BJ. Administration-time differences in the pharmacokinetics of gentamicin intraveneously delivered to human beings. Chronobiol Int 1999; 16: 821-9.
10. Canal P, Sqalli A, de Forni M, et al. Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 1991; 40: 287-91.
11. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21-9.
12. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-24.
13. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-46.
14. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus Type 1-infected protease inhibitor experienced patients. J Infect Dis 2002; 185: 599-607.
15. Eron JJ, Feinberg JH, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral naïve HIV-positive patients: a 48 week randomized clinical trial. J Infect Dis 2004; 189: 265-72.
16. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naïve patients, 48-week results. 11th Conference on Retrovirus and Opportunistic Infections, February 8-11, 2004, San Francisco, CA (abstract 570).
17. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J AIDS 2003; 32: 287-91.
18. Cato A, III Cao G, Hsu A, Cavanaugh J, Leonard J, Granneman R. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 1997; 25: 1104-6.
19. Ouellet D, Hus A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998; 64: 355-62.
20. Back DJ, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16: S5-S37.
21. Acosta E, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retrovirus 2002; 18: 825-34.
22. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir/ritonavir in combination with efavirenz and two nucleoside reverse-transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrobial Agents Chemother 2003; 47: 350-9.
23. Capparelli E, Goebel FD, William I, et al. Nelfinavir (NFV) population pharmacokinetics (PK) in long-term suppressors compared with the PK of the new 625 mg formulation in healthy volunteers. Clin Pharmacol Ther 2004; 75: P32 (abstract PI-111).
24. Petersen C, Pun E, Strada R., et al. Pharmacokinetics of nelfinavir (Viracept 250 mg tablet): effect of food intake on single-dose PK parameters. 10th Conference on Retroviruses and Opportunistic Infections February 10-14 2003; Boston, MA [abstract 544].
25. Kurowski M, Kaeser B, Sawyer A, et al. Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice-daily. Eur J Med Res 2002; 7: 453-6.
26. Le Guellec C, Rodon P, Bastides F, et al. Bayesian estimation of nelfinavir exposure based on a model integrating diurnal and food-effects. 5th International Workshop on Clinical Pharmacology in HIV Therapy, April 1-3, 2004; Rome, Italy (abstract 6.13).
27. Product information Norvir (ritonavir). Abbott Laboratories, Chicago, IL, Revised October 2003.
28. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
29. Product information Kaletra (lopinavir/ritonavir). Abbott Laboratories, Chicago, IL, Revised January 2003.
30. Bertz R, Renz C, Foit C, et al. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg bid) in HIV-infected subjects when taken with food. 2nd International Workshop on Clinical Pharmacology in HIV Therapy, April 2-4, 2001; Noordwijk, The Netherlands (abstract 3.10).